Management of Choledochal Cysts

Understanding Choledochal Cysts

• Choledochal cysts are congenital malformations of the biliary system with prevalence varying from 1:100,000 in Western countries to 1:13,000 in Japan, categorized according to the Todani classification based on location, shape, and multiplicity 1

Clinical Presentation

• Patients may present with jaundice (84-90%), weight loss (35%), abdominal pain (30%), nausea and vomiting (12-25%), and fever (10%) 2
• Many patients are asymptomatic and diagnosed incidentally 2

Diagnostic Approach

• Contrast-enhanced MRI with magnetic resonance cholangiopancreatography (MRCP) is superior for accurate assessment of biliary obstruction 3
• Contrast-enhanced CT is an alternative but less accurate than MRI/MRCP 3
• Ultrasound is often the first imaging modality but has limitations in fully characterizing the cyst 3

Treatment Algorithm

• Complete excision of the choledochal cyst with Roux-en-Y hepaticojejunostomy is the treatment of choice, as recommended by the American Association for the Study of Liver Diseases, to prevent potential malignant transformation and recurrent complications 4

Post-Treatment Management and Surveillance

• Patients with choledochal cysts should undergo surveillance after resection due to the risk of metachronous cancer, with recommended follow-up including liver function tests and CA19-9 annually for 20 years (then biannually) 1
• Ultrasound should be performed biannually for 20 years (then every 3 years) 1
• The risk of malignancy appears primarily limited to the first 20 years after resection 1

Choledochal Cyst Classification and Malignancy Risk

Definition and Classification

• Type I (solitary, extrahepatic) and Type IV (intra- plus extrahepatic) bile duct cysts have the greatest predisposition to malignancy 5

Characteristics of Choledochal Cysts

Epidemiology and Pathophysiology

• Choledochal cysts occur 3-8 times more frequently in females than males, according to the BioScience Trends journal 6
• The condition is considered rare in Western countries, which contributes to potential diagnostic delays 7
• Over 90% of patients with choledochal cysts have an anomalous pancreaticobiliary duct junction, with the pancreatic duct joining the common bile duct >1 cm proximal to the ampulla, as reported by BioScience Trends 6, 7
• This anomalous junction allows pancreatic enzymes to reflux into the biliary system, contributing to inflammation, biliary epithelial damage, and increased risk of malignancy 6

Clinical Significance and Management

• Cases registered with the Japanese Study Group on Pancreaticobiliary Maljunction over a 10-year period indicated that the incidence of cholangiocarcinoma is 7.0% in cases of pancreaticobiliary maljunction with dilated bile ducts (choledochal cysts) 7
• Patients may present with jaundice (84-90%), weight loss (35%), abdominal pain (30%), nausea and vomiting (12-25%), and fever (10%) 7

Management of Choledochal Cysts

Treatment Rationale

• The American College of Radiology recommends stabilizing patients with acute cholangitis with sepsis using antibiotics, such as third-generation cephalosporins, ureidopenicillins, carbapenems, or fluoroquinolones, before proceeding to definitive cyst excision 8

Formation Mechanism of Choledochal Cysts

Embryological Basis

• The American Association for the Study of Liver Diseases notes that choledochal cysts arise from abnormal embryonic ductal plate development, where the ductal plate disconnects from the biliary tree and progresses into cystic structures, with over 90% of cases associated with an anomalous pancreaticobiliary duct junction that allows reflux of pancreatic enzymes into the biliary system 9
• The ductal plate is a double cylinder of hepatoblasts that encircles portal vein branches and provides the scaffold for normal bile duct development, and when this maturation process is arrested or disrupted, the ductal plate disconnects from the biliary tree instead of properly integrating 9
• These disconnected segments then progress into cystic structures rather than forming normal bile ducts, due to the abnormal development of the ductal plate 9

Pathophysiological Mechanism

• The epithelial cells lining the cyst retain secretory function, producing fluid that generates positive luminal pressure contributing to cyst expansion 9

Cyst Fluid Characteristics

• The fluid within choledochal cysts consists primarily of water and electrolytes, and is devoid of bile acids or bilirubin, reflecting the disconnection from normal biliary flow and the contribution of pancreatic secretions 9

Classification Context

• The Todani classification system categorizes choledochal cysts by location and extent, and Type V (Caroli disease) is characterized by isolated intrahepatic bile duct dilatation 9

Management of Intrahepatic Choledochal Cyst

Introduction to Treatment

• The American Academy of Pediatrics and other medical societies recommend complete surgical excision of the intrahepatic cyst component combined with extrahepatic cyst excision and Roux-en-Y hepaticojejunostomy as the definitive treatment for Type IV choledochal cysts with intrahepatic involvement, due to the high risk of malignant transformation, with a 7.0% incidence of cholangiocarcinoma in pancreaticobiliary maljunction cases 10

Surgical Management

• Complete excision of the extrahepatic choledochal cyst with cholecystectomy, hepaticoenterostomy at the porta hepatis with partial resection of the intrahepatic cyst wall, and Roux-en-Y hepaticojejunostomy for biliary-enteric reconstruction are necessary to address both extrahepatic and intrahepatic components, with the goal of preventing malignant transformation and recurrent complications 10

Acute Management and Adjunctive Therapies for Choledochal Cysts

Medical Therapy for Caroli Disease

Management of Acute Cholangitis

Endoscopic Drainage for Biliary Obstruction without Sepsis

Risk of Malignancy and Guideline Recommendations for Asymptomatic Type I Choledochal Cysts

Malignancy Risk in Pancreaticobiliary Maljunction

• In patients with pancreaticobiliary maljunction, the incidence of cholangiocarcinoma is approximately 7 %, underscoring a substantial malignant potential of choledochal cysts. 15

Guideline Recommendation

• The Japanese Society of Hepatobiliary‑Pancreatic Surgery explicitly recommends complete excision of the extra‑hepatic biliary tract and cholecystectomy in individuals with pancreaticobiliary maljunction and dilated bile ducts (choledochal cysts), even when they are asymptomatic, to prevent cancer development. 15